Table 2.
Subgroup analyses of randomized clinical trials of apremilast for PASI-75 in psoriasis.
| Factor | Trails, No. | Apremilast/placeboParticipants, No. | RR (95% CI) | P value | I2, %;P value |
|---|---|---|---|---|---|
| Therapeutic Dose | |||||
| 10mg bid | 1 | 89/88 | 1.98 (0.70 to 5.55) | 0.20 | NA |
| 20mg bid | 7 | 607/580 | 2.82 (2.01 to 3.95) | < 0.00001 | 3; 0.40 |
| 30mg bid | 10 | 1597/1069 | 4.08 (3.12 to 5.33) | < 0.00001 | 17; 0.29 |
| 20mg qd | 1 | 87/87 | 1.00 (0.42 to 2.40) | 1.00 | NA |
| Treatment Course | |||||
| 12 weeks | 1 | 173/87 | 1.66 (0.82 to 3.35) | 0.16 | NA |
| 16 weeks | 9 | 2052/1004 | 3.78 (2.97 to 4.81) | < 0.00001 | 0; 0.57 |
| 24 weeks | 2 | 336/154 | 2.47 (1.41 to 4.31) | 0.002 | 0; 0.75 |
| Clinical Phenotype | |||||
| PsA with plaque psoriasis | 4 | 706/321 | 2.48 (1.76 to 3.50) | < 0.00001 | 0; 0.84 |
| plaque psoriasis | 7 | 1674/835 | 3.67 (2.72 to 4.97) | < 0.00001 | 18; 0.27 |
NA, not applicable; PsA, psoriatic arthritis; RR, relative risk.